Comparison of Letrozole with Elagolix for Medical Management of Endometriosis Associated Pain

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250818011

Enrollment

120

Registered

2025-08-18

Start date

2025-08-31

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

women presenting with endometriosis related pain endometriosis VAS pain score

Interventions

Oral Letrozole 2.5 mg along with elemental Calcium 1000 mg and vitamin D 880 IU daily,Oral Elagolix 150 mg once daily

Experimental Drug,Active Comparator Drug

Letrozole,Elagoliz

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: women of reproductive age (18-45 years), reporting at least one type of endometriosis related pain, and failure of previous treatment

Exclusion criteria

Exclusion criteria: Pregnant, Pulmonary, cardiac, renal or hepatic disease, or Undiagnosed vaginal bleeding

Design outcomes

Primary

Measure	Time frame
Pain score reduction 0, 3, & 6 month VAS pain score	—

Secondary

Measure	Time frame
Side effects At every consultation VAS nausea & vomit	—

Countries

Pakistan

Contacts

Public ContactShamila Munir

Fatima Jinnah Medical University

shamilaijaz@yahoo.co.uk924299200572

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026